An interventional study of acupuncture in Intestinal Disorder, Inflammatory Bowel Diseases and Crohn Disease, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Recruiting at 2 sites in China. Open to participants aged 16 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 192 studies in Crohn Disease with a site in China — 75 open to participants now, 88 under way, 22 of them phase 3. Crohn Disease · China.
Among the 192 studies in Crohn Disease with a site in China, this one is the 92nd largest by planned enrollment of the 129 interventional ones that give a count, is one of 8 that started in 2019, is one of 49 with no phase, reaches primary completion later than 32 of the 87 other live ones, and was the 57th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →75 of the 192 studies in Crohn Disease with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 27 more countries
Ages 18+
Benethera (Shaoxing) Biotechnology Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Belgium and 7 more countries
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 22 · Phase 3 35 · Phase 4 13
First in 2009; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 110 across the 129 interventional studies, 198 across the 63 observational. Of the 67 that completed or were terminated, 12 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 192 have an industry lead sponsor. The 10 most frequent:
Shanghai Institute of Acupuncture, Moxibustion and Meridian is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Shanghai Institute of Acupuncture, Moxibustion and Meridian has 9 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
24 of the studies in Crohn Disease with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06925594Phase 3Jiangsu Topcel-KH Pharmaceutical Co., Ltd.Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease | 2026-12-28 |
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT05906576Taizhou Mabtech Pharmaceutical Co.,LtdPost-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients | 2026-11 |
Add all 24 to your calendar (.ics) → With an account.
Among the 192 studies in Crohn Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To observe the clinical effect of acupuncture on Crohn's disease (CD) and its influence on brain function activity and the TRY-KYN metabolism level, and to screen the brain image markers of acupuncture on CD
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
This study's planned enrollment of 60 is below the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Shanghai Institute of Acupuncture, Moxibustion and Meridian is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Compared within Crohn Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Intestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving acupuncture and mild moxibustion.
Other: acupuncture
Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
Clinical remission
Crohn's disease activity index (CDAI)less than 150 and decreased more than 70
Time frame: Week 12
Clinical remission
Crohn's disease activity index (CDAI) less than 150 and decreased more than 70
Time frame: Week 24, 36 and 48
Clinical response
Crohn's disease activity index (CDAI) decreased more than 70
Time frame: Week 12, 24, 36 and 48
Crohn's disease activity index (CDAI)score
The mean change in CDAI from baseline. The higher the score, the worse the condition. Greater than 0, no upper limit.
Time frame: Week 12, 24, 36 and 48
laboratory test
serum C-reactive protein (CRP) level
Time frame: Week 12, 24, 36 and 48
laboratory test
Erythrocyte sedimentation rate (ESR)
Time frame: Week 12, 24, 36 and 48
laboratory test
Platelet count
Time frame: Week 12, 24, 36 and 48
Inflammatory bowel disease questionnaire (IBDQ)
The mean change in IBDQ from baseline. The higher the score, the worse the condition.The score is range from 32 to 224.
Time frame: Week 12 and 24
Crohn's disease endoscopic index of severity (CDEIS)
The mean change in CDEIS from baseline
Time frame: Week 48
Hospital anxiety and depression scale (HADS)
The mean change in HADS from baseline. The higher the score, the more serious the disease. The depression and anxiety score is range from 0 to 21.
Time frame: Week 12 and 24
The proportion of recurrences
Defined as CDAI \> 150 and increase ≥ 70 points or need to adjust drug to control disease condition.
Time frame: Week 48
Brain functional and structural changes
measured by functional MRI
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal Indoleamine2,3dioxygenase 1 (IDO1)level
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal Tryptophan (TRP) level
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal kynurenine (KYN)level
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal kynurenic acid (KYNA) level
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal quinolinic acid (QUIN) level
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal IFN-gamma level
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal IL-1beta level
Time frame: Week 12
Plasma and intestinal TRP-KYN metabolism level
Plasma and intestinal IL-18 level
Time frame: Week 12
Analysis of intestinal microbes
Application of 16S sequencing to analyze the gut microbial composition, structure and diversity of patients.
Time frame: Week 12
Analysis of the association between gut microbes, brain imaging and behavior
The pearson correlation and linear regression models were applied to establish the association between gut microbes, brain function and structure and behavior in an attempt to explore the relationship between the gut microbe-gut-brain axis in patients with active CD.
Time frame: Week 12
Acupuncture efficacy prediction
Deep learning algorithms such as artificial neural networks and support vector machines were applied to construct and validate an acupuncture efficacy prediction model based on MRI changes in high and low response patients in the acupuncture group, and to screen brain neuroimaging markers that predict the effective relief of CD disease activity by acupuncture.
Time frame: Week 48
Disease activity prediction
Differences in brain structure and functional activity between active CD patients and remitting CD patients as well as healthy subjects are measured, and deep learning algorithms such as artificial neural networks and support vector machines are applied to construct and validate disease diagnostic models and screen brain imaging markers that predict CD disease activity.
Time frame: Week 0
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2019 (actual). Primary completion is estimated for Dec 2026, 90 months after the start.
Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 90 months is above that.
Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Institute of Acupuncture, Moxibustion and Meridian